Basil Drugs And Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.50 M
as on 18-07-2024
- Paid Up Capital ₹ 5.50 M
as on 18-07-2024
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.93 M
as on 18-07-2024
- Revenue -31.56%
(FY 2023)
- Profit -53.03%
(FY 2023)
- Ebitda -25.33%
(FY 2023)
- Net Worth 387.80%
(FY 2023)
- Total Assets 62.44%
(FY 2023)
About Basil Drugs And Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.50 M and a paid-up capital of Rs 5.50 M.
The company currently has active open charges totaling ₹2.93 M.
Anup Singh and Priyamvada Singh serve as directors at the Company.
- CIN/LLPIN
U24303MH2018PTC304632
- Company No.
304632
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jan 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Basil Drugs And Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anup Singh  | Director | 24-Jan-2018 | Current |
| Priyamvada Singh | Director | 24-Jan-2018 | Current |
Financial Performance and Corporate Structure Insights of Basil Drugs And Pharmaceuticals.
Basil Drugs And Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 31.56% decrease. The company also saw a substantial fall in profitability, with a 53.03% decrease in profit. The company's net worth Soared by an impressive increase of 387.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Basil Drugs And Pharmaceuticals?
In 2023, Basil Drugs And Pharmaceuticals had a promoter holding of 78.00% and a public holding of 22.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 20 May 2022 | ₹0.98 M | Open |
Hdfc Bank Limited Creation Date: 20 May 2022 | ₹0.49 M | Open |
Hdfc Bank Limited Creation Date: 12 May 2022 | ₹0.49 M | Open |
How Many Employees Work at Basil Drugs And Pharmaceuticals?
Basil Drugs And Pharmaceuticals has a workforce of 20 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Basil Drugs And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Basil Drugs And Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
